Researcher points to new antipsychotic therapy class

A research team at the Flanders Institute for Biotechnology, VIB, and University of Leuven have found that a fault in the neuregulin protein plays a key role in the development of schizophrenia--an insight likely to spur new development programs for the disease. The team concluded that a faulty "cleavage" of the nrg-1 protein--normally done by a pair of molecular scissors--is at the basis of schizophrenia. And the scientists speculated that a new therapy that did the work of the scissors could be on the cutting edge of a new class of antipsychotic therapies.

"As this is fundamental research, there are no immediate implications for diagnosis and treatment, but our results strengthen the case for an involvement of abnormal neuregulin signaling in schizophrenia and are bound to increase the interest in the clinical testing of drugs that modulate neuregulin signaling," said the scientists.

- read the report in the Telegraph

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.